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Abstract 
Background: The clinical and histological characteristics of salivary gland tumors vary widely, complicating their 
diagnosis and management, and major differences have been recorded in the distribution of histopathological 
diagnoses among different countries.
Material and Methods: This retrospective study reviewed the demographic (age, sex) and clinicopathological 
(pathology diagnosis and localization) characteristics of cases diagnosed with primary SGC between June 1992 
and May 2014 in the Pathology Department of the 12 de Octubre Hospital of Madrid. Diagnoses were recorded 
according to the 2005 WHO classification. 
Results: The study included 149 SCG patients, aged between 11 and 94 yrs, with mean age at onset of 55.56 yrs 
and peak incidence in the eighth decade of life. The male:female ratio was 1.01. The parotid gland was the most 
frequently involved (75.2%). The most frequent carcinoma was mucoepidermoid carcinoma (24.2%), followed by 
acinic cell carcinoma (15.4%).  
Conclusions: The demographic and histopathological characteristics of patients with salivary gland carcinomas in 
Spain, reported here for the first time, are broadly similar to those found in other countries. 
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Introduction
The human body contains three major salivary glands 
(parotid, submandibular, and sublingual) and hundreds 
of minor salivary glands distributed throughout the 
upper aerodigestive tract. Numerous types of tumor 
originate in the salivary glands, and their histopathol-
ogy is considered to be more complex and diverse than 
that of tumors at other anatomic sites (1). Malignant 
neoplasms of salivary glands constitute 1% - 3% of all 
head and neck cancers and only 0.3% of all malignant 
neoplasms (2). The reported incidence of malignant and 
benign salivary gland neoplasms in different counties 
has ranged between 0.2 and 9.7 and between 1.1 and 2.9 
per 100,000 inhabitants, respectively (3). The clinical 
and histological characteristics of salivary gland tumors 
vary widely, complicating their diagnosis and manage-
ment (4), and major differences have been recorded in 
the distribution of histopathological diagnoses among 
different countries (5-7). This drawback was addressed 
by the WHO in 2005 with a reclassification of these 
neoplasms and the introduction of new entities, estab-
lishing 38 subtypes divided between epithelial and mes-
enchymal cases. Data on the distribution of subtypes 
and the characteristics of patients are useful to improve 
our understanding of this disease, but no such informa-
tion has been published on the distribution of salivary 
gland carcinomas in Spain. The objective of this study 
was to determine the distribution of demographic and 
histopathological characteristics in patients with SGC 
in a Spanish hospital population.
Material and Methods
Clinicopathological data of patients with primary ma-
lignant neoplasms of epithelial salivary gland origin 
were gathered from patients diagnosed in the Pathology 
Department of the 12 de Octubre Hospital of Madrid 
between June 1992 and May 2014. This type of tumor 
is treated by multiple specialists, including maxil-
lofacial surgeons, otolaryngologists, dentists, plastic 
surgeons, and radiotherapists. Treatment was not con-
sidered in this study because the therapeutic approach 
varies among the specialties involved. A biopsy report 
was available for all diagnosed cases. The demographic 
and clinical characteristics reviewed include sex, age, 
localization, and histological type.
IBM SPSS Statistics 22 for Windows was used for the 
statistical analysis. Only definitive diagnoses were con-
sidered in the histopathological analysis and only primary 
lesions derived from salivary glands were included, ex-
cluding benign tumors, mesenchymal tumors, congenital 
anomalies, congenital cysts, chronic sialadenitis, sialo-
lithiasis, vascular and lymphatic malformations, salivary 
or mixed cysts, granulomatous infections, and salivary 
gland invasions of skin carcinomas. All cases were re-
corded according to the 2005 WHO classification. 
The current study was approved by Ethical Comitte of 
the 12 de Octubre Hospital (Nº CEIC 15/ 177).
Results
A total of 149 cases with salivary gland carcinomas met 
the inclusion criteria between June 1992 and May 2014 
and were reviewed in this study.
-  Sex and age
The age of patients at diagnosis ranged between 11 and 
94 yrs, with a mean (standard deviation [SD] age of 55.66 
(20.0) yrs and a peak incidence in the eighth decade of 
life. Three cases (2%) were diagnosed in pediatric age 
(<16 yrs). The study included 75 males (50.3%) and 74 
females (49.7%), a male:female (M:F) ratio of 1.01. 
The mean age at onset was lower in females (52.92 
[21.3] yrs) than in males (58.43 [18.3] yrs). The age at 
diagnosis was 35.33 (14.01) yrs in patients with basal 
cell carcinoma, 47.8 (21.03) yrs in those with mucoepi-
dermoid carcinoma (MEC), 47.8 (19.80) yrs in those 
with adenoid cystic carcinoma (ACC), 49.8 (18.63) yrs 
in those with acinic cell carcinoma (AcCC), 50.9 (18.56) 
yrs in those with carcinoma ex-pleomorphic adenoma, 
50.9  (9.17) yrs In those with PLGA; 70.8 (14.01) yrs in 
those with squamous cell carcinoma (SCC), and 88 yrs 
in the patient with large cell carcinoma (Fig. 1).
- Localization
The most frequent tumor localization in our series was 
the parotid gland (n=108, 72.5%) followed by the sub-
mandibular gland (n= 22, 14.8%), minor salivary glands 
(n=16, 10.7%), and sublingual gland (n=3, 2%) (Fig. 2). 
Among minor salivary glands , the most frequent locali-
zation was the lip (n=5), followed by soft palate (n=4), 
buccal mucosa (n=3), and genian area (n=2). 
- Histological diagnosis 
The most frequent carcinoma in our series was MEC 
(n=36, 24.2%), followed by AcCC (n=23; 15.4%), SCC 
(n=17; 11.4%), and ACC (n=16; 10.8%). MEC was equal-
ly prevalent in males and females (M:F=1), while SCC 
showed the highest male-female ratio (3.25). Myoepi-
thelial carcinoma was the most frequent among females 
(M:F=0.33), followed by AcCC. Among males, SCC was 
the second most frequent, followed by ACC (Table 1). 
PLGA (n=9) was only observed in minor salivary glands, 
where it was the most frequent type (56.3%). Among 
the 23 cases of AcCC, 22 (95.7%) were in the parotid 
gland, where it was the second most frequent type after 
MEC. In the submandibular gland, the most frequent 
type was MEC (n=6), followed by SCC (n=5) and ACC 
(n= 5) (Table 2). Submandibular gland involvement was 
more frequent among males (n=18, 81.8%) than among 
females (n=4, 18.2%); while parotid gland involvement 
was more frequent among females (n=61; 56.5%) than 
among males (n=47; 43.5%). There was no gender dif-
ference in minor salivary glands involvement (50%).
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Discussion
This study reports on the demographic distribution of 
patients with different salivary gland carcinomas treat-
ed at a major regional Spanish hospital serving around 
750,000 patients. Little information is available on the 
characteristics of salivary gland carcinomas patients 
in Spain. One study reported a low incidence of major 
salivary gland carcinomas in this country that tended 
to decrease between 1991 and 2001 (8) contrasting with 
reports of an increasing incidence in some other coun-
tries, including the USA (9). This discrepancy may be 
attributable to differences in behaviors and risk factors 
among populations.
The mean age of the 149 salivary gland carcinomas pa-
tients in the present study was 55.6 yrs, within the range 
of reports in the literature from 45.2 (10) to 58.6 yrs (11). 
The peak incidence was in the eighth decade, much old-
er than observed in Asia and Nigeria (10-16) and older 
Fig. 1. Mean age by histological type. AD-NOS= adenocarcinoma not otherwise specified, PLGA= polymorphous low grade adenocarcinoma, 
AcCC = acinic cell carcinoma, ACC= adenoid cystic carcinoma, SCC=squamous cell carcinoma, CEXPA = carcinoma ex-pleomorphic ad-
enoma, C = undifferentiated carcinoma, and MEC= mucoepidermoid carcinoma.
Fig. 2. Distribution of salivary gland carcinomas by site (n= 149).
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Diagnosis Male Female Total Ratio M:F
Ductal adenocarcinoma 8 (10,7%) 4 (5,4%) 12 (8,1%) 2
AD-NOS 3 1 4 (2,7%) 3
Polymorphouslow-grade ade-
nocarcinoma 3 6 9 (6,1%) 0,5
Acinic cell carcinoma 7 16 23 (15,4%) 0,44
Large cell carcinoma 0 1 1 (0,7%) -
Adenoid cystic carcinoma 10 6 16 (10.8%) 1,67
Basal cell adenocarcinoma 1 2 3 (2%) 0,5
Clear cell carcinoma 1 0 1 (0,7%) -
Small cell carcinoma 0 1 1 (0,7%) -
Squamous cell carcinoma 13 4 17 (11,4%) 3,25
Ephitelial-myoephitelial car-
cinoma 0 3 3 (2%) -
Carcinoma ex pleomorphic 
adenoma 7 6 13 (8,7%) 1,17
Myoephitelial carcinoma 1 3 4 (2,7%) 0,33
Mucoepidermoid carcinoma 18 18 36 (24,2%) 1
Carcinosarcoma 1 0 1 (0,7%) -
Cystoadenocarcinoma 1 0 1 (0,7%) -
Undifferentiated carcinoma 1 3 4 (2,7%) 0,33
Total 75 74 149 (100%) 1,01
Table 1. Classification of salivary gland carcinomas by diagnosis and sex.
Parotid gland
Submandibular
gland
Sublingual 
gland
Minor  sali-
vary glands
Total
Ductal adenocarcinoma 11 (91,7%) - 1 (8,3%) - 12 (100%)
AD-NOS 3 (75%) 1 (25%) - - 4
Polymorphouslow-grade ade-
nocarcinoma - - - 9 (100%) 9 (100%)
Largue cell adenocarcinoma 1 (100%) - - - 1 (100%)
Acinic cell carcinoma 22 (95,7%) - - 1 (4,3%) 23 (100%)
Adenoid cystic carcinoma 7 (43,7%) 5 (31,2%) 1 (6,3%) 3 (18,8%) 16 (100%)
Basal cell carcinoma 3 (100%) - - - 3 (100%)
Clear cell carcinoma - - - 1 (100%) 1 (100%)
Small cell carcinoma 1 (100%) - - - 1 (100%)
Squamous cell carcinoma 11 (64,7%) 5 (29,5%) - 1 (5,8%) 17 (100%)
Ephitelial-myoephitelial car-
cinoma 3 (100%) - - - 3 (100%)
Carcinoma ex –Adenoma 
pleomorphous 10 (76,9%) 3 (23,1%) - - 13 (100%)
Undifferentiated carcinoma 4 (100%) - - - 4(100%)
Myoephitelial carcinoma 3 (75%) 1 (25%) - - 4 (100%)
Mucoepidermoid carcinoma 28 (77,8%) 6 (16,6%) 1 (2,7%) 1 (2,7%) 36 (100%)
Carcinosarcoma - 1 (100%) - - 1 (100%)
Cystoadenocarcinoma 1 (100%) - - - 1 (100%)
Total 108 22 3 16 149 (100%)
Table 2. Distribution of salivary gland carcinomas by site (n= 49).
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than the seventh decade reported in Brazil (6) and the 
fifth decade in Mexico (17). There was no gender dif-
ference in the present study, with a male:female ratio 
of 1, similar to findings by Luksic et al. (1), Wang et al. 
(5), and Tian et al. (15). However, various authors have 
found salivary gland carcinomas to be more frequent in 
females (11,13,18,19). Thus, a male:female ratio of 0.96 
was reported in one of the longest series, derived from 
a review of cases in Sweden over a period of almost 30 
years records (20) and a ratio of 0.42 in Jordan (7). In 
contrast, salivary gland carcinomas were found to be 
more frequent in males than in females by some other 
researchers (3,6,10,14,16,21). Table 3 summarizes the 
histologic diagnoses reported in the literature.
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The parotid gland was the most frequent localiza-
tion (72.5%) in our study, as in most large case series 
(3,5,10-12,14,20). However, minor salivary glands were 
the most frequent site in some other studies (7,13,15,18) 
and were the second most frequent in most reports 
(3,6,10,11,14,20,21). The type of center in which cas-
es originate may affect this result, given that univer-
sity centers are more likely to encounter minor sali-
vary glands lesions than major salivary gland lesions, 
which are generally treated in hospital settings. In the 
present series, the submandibular gland was the sec-
ond most frequent localization, followed by minor sali-
vary glands, similar to the report by Saghravanian et 
al. (22), in which 16.25% of cases were minor salivary 
glands. It should be taken into account that the biopsy 
results are classified by anatomic site in our hospital 
and some minor salivary glands may be categorized as 
of intraoral rather than salivary gland origin, produc-
ing a possible underestimation. Only 2% of the salivary 
gland carcinomas were in the sublingual gland, consist-
ent with previous findings of the very low prevalence 
(1,3,5,10,12,13,15,18,20) or absence of cases at this site 
(6,7,14,17,21), although a prevalence of 7% was reported 
in one study (11). Among the minor salivary glands, the 
most frequent salivary gland carcinomas localization 
was the palate, as also reported in other similar series 
(1,3,5,7,16).
MEC was the most frequent histopathological 
diagnosis (24.2%), as found by various authors 
(5,6,11,13,18,19,21,22) followed by AcCC (15.4%) and 
SCC (11.4%). In some other series, the percentages of 
MEC and ACC cases were similar (10,15) or ACC was 
the most frequent (3,7,5,12,14,16,20). It should be bor-
ne in mind that ACC frequently affects minor salivary 
glands and that PLGA was considered an ACC in the 
past (6). Since its first description in 1983, a relatively 
high frequency of PLGA has been reported in some 
studies (23). Both ACC and PLGA show a cribriform 
morphology and perineural infiltration; therefore, the 
differential diagnosis, which is highly critical for the 
management and prognosis of patients, can be difficult 
in a small biopsy (24). In our series, 6.1% of salivary 
gland carcinomas were PLGAs, similar to findings of 
Al-kateeb et al. (7), and they were all localized in minor 
salivary glands. A study by de Souza et al. (8) found di-
fferences in PLGA frequency between continents, ran-
ging from 3.9% in Asia to 20% in Oceanía, consistent 
with data recently published by Wang et al. (5). Luk-
sic ateeb and Ababneh (7) reported no cases of PLGA, 
which may in part explain why ACC was the most fre-
quent diagnosis (43.3%). Kizil et al. (3) observed PLGA 
in 5.9% of cases and, although ACC was the most fre-
quent, the percentage of cases was lower (25.7%). A hig-
her percentage of SCC cases (11.4%) was recorded in 
the present series than in other studies (1,6,18,20), and 
one explanation may be the classification of high-grade 
MECs as SCCs or undetermined adenocarcinomas in 
some cases (13). In most studies, either MEC or ACC 
was the most frequent diagnosis. AcCC was the second 
most frequent diagnosis in our patients (15.4%), with a 
similar frequency to that reported in Mexico (19) and 
Jordan (7). According to the WHO in 2005 and Kizil 
et al. (3), the AcCC is slightly more common among 
females, and in our series, the male:female ratio was 
0.44. PLGA was more frequent in females, as also re-
ported by Jones et al. (18). According to other authors, 
ACC (4,14) and SCC (3) were more frequent in males. 
The mean ages at diagnosis in our series were consis-
tent with the few published data on this variable, being 
around 50 years of age for ACC (3) and MEC (3,6) and 
higher (70.8 yrs) for SCC (5,18) .
In summary, the distribution of salivary gland carcino-
mas in this Spanish population, including the histologi-
cal type and the age and sex of patients, was similar to 
previous reports in different countries (Table 3) except 
for a higher frequency of AcCC and SCC cases. These 
results confirm the higher frequency of AcCC and 
PLGA in females and of SCC and ACC in males. Fur-
ther epidemiological studies in European populations 
are warranted to improve understanding of salivary 
gland carcinomas and develop strategies for their early 
diagnosis and management.
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